Bliss GVS Pharma Limited has announced its Q2 2025 financial results during a Board Meeting held on November 6, 2025. The meeting concluded with the approval of the unaudited standalone and consolidated financial results for the quarter and half-year ending September 30, 2025. The company has provided a Limited Review Report from its auditors along with these results. This disclosure aligns with the SEBI Listing Obligations and Disclosure Requirements, ensuring compliance with regulatory standards.

In addition to the financial results, the Board approved the appointment of Mr. Shreekrushna Joshi as Senior Management Personnel, effective immediately. This decision came after a recommendation from the Nomination and Remuneration Committee. The meeting, which started at 4:30 PM and ended at 6:10 PM, also included details required under recent SEBI circulars. The company's stock is listed under the symbol BLISSGVS on the National Stock Exchange of India and has the scrip code 506197 on the Bombay Stock Exchange.